Literature DB >> 24367026

Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathies.

Mahalakshmi Ramadass1, Berhane Ghebrehiwet, Richard J Smith, Richard R Kew.   

Abstract

The complement system is tightly regulated to safeguard against tissue damage that results from unwanted activation. The key step of C3 cleavage to C3b is regulated by multiple mechanisms that control the initiation and extent of activation. This study demonstrated that C3b:plasma protein complexes form in the fluid-phase during complement activation. Several different plasma proteins displayed a discrete high molecular SDS-resistant band when any of the three complement activating pathways were triggered in normal human serum or plasma. Serum depleted of individual complement proteins revealed that C3 and factors B and D were essential for complex formation. Inactivation of the thioester bond in C3 also prevented complex formation. In vitro, complexes could be generated using four purified proteins-C3, factor B, factor D, and target protein-and Mg(2+) to allow C3 convertase formation. These studies showed that the complexes consisted of a plasma protein covalently bound to C3b in a 1:1 molar ratio; the C3b portion was rapidly degraded by factors H and I. Analysis of plasma samples from patients with dense deposit disease and C3 glomerulonephritis demonstrated that C3b:protein complexes form spontaneously in the blood of patients with dense deposit disease and, to a lesser extent, in C3 glomerulonephritis patients, but not in healthy controls. This finding supports the underlying hypothesis that these C3 glomerulopathies are diseases of fluid-phase complement dysregulation. These complexes could normally function as a passive mechanism to intercept C3b from depositing on host cells. However, excessive generation and/or defective clearance of fluid-phase C3b:protein complexes may have pathological consequences.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24367026      PMCID: PMC3897554          DOI: 10.4049/jimmunol.1302288

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up.

Authors:  R Schwertz; U Rother; D Anders; N Gretz; K Schärer; M Kirschfink
Journal:  Pediatr Allergy Immunol       Date:  2001-06       Impact factor: 6.377

2.  Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity.

Authors:  G D Ross; J D Lambris; J A Cain; S L Newman
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

3.  C3b inactivator deficiency with immune complex manifestations.

Authors:  P Solal-Celigny; M Laviolette; J Hebert; P C Atkins; M Sirois; G Brun; G Lehner-Netsch; J M Delâge
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

4.  Covalent binding and hemolytic activity of complement proteins.

Authors:  S K Law; N A Lichtenberg; R P Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

5.  The covalent-binding reaction of complement component C3.

Authors:  R B Sim; T M Twose; D S Paterson; E Sim
Journal:  Biochem J       Date:  1981-01-01       Impact factor: 3.857

Review 6.  Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis.

Authors:  J S Cameron; D R Turner; J Heaton; D G Williams; C S Ogg; C Chantler; G B Haycock; J Hicks
Journal:  Am J Med       Date:  1983-02       Impact factor: 4.965

7.  Neutrophil recruitment to the lung in both C5a- and CXCL1-induced alveolitis is impaired in vitamin D-binding protein-deficient mice.

Authors:  Glenda Trujillo; David M Habiel; Lingyin Ge; Mahalakshmi Ramadass; Nancy E Cooke; Richard R Kew
Journal:  J Immunol       Date:  2013-06-10       Impact factor: 5.422

8.  Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

9.  Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

10.  Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

View more
  10 in total

1.  Complement Factor H Binds to Human Serum Apolipoprotein E and Mediates Complement Regulation on High Density Lipoprotein Particles.

Authors:  Karita Haapasalo; Kok van Kessel; Eija Nissilä; Jari Metso; Tiira Johansson; Sini Miettinen; Markku Varjosalo; Juha Kirveskari; Pentti Kuusela; Angelika Chroni; Matti Jauhiainen; Jos van Strijp; T Sakari Jokiranta
Journal:  J Biol Chem       Date:  2015-10-14       Impact factor: 5.157

Review 2.  Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.

Authors:  An S De Vriese; Sanjeev Sethi; Jens Van Praet; Karl A Nath; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-07-16       Impact factor: 10.121

3.  Enhanced recognition of plasma proteins in a non-native state by complement C3b. A possible clearance mechanism for damaged proteins in blood.

Authors:  Mahalakshmi Ramadass; Berhane Ghebrehiwet; Richard R Kew
Journal:  Mol Immunol       Date:  2014-11-15       Impact factor: 4.407

4.  Treating C3 glomerulopathy with eculizumab.

Authors:  Thomas Welte; Frederic Arnold; Julia Kappes; Maximilian Seidl; Karsten Häffner; Carsten Bergmann; Gerd Walz; Elke Neumann-Haefelin
Journal:  BMC Nephrol       Date:  2018-01-12       Impact factor: 2.388

5.  Complement Factor H and Apolipoprotein E Participate in Regulation of Inflammation in THP-1 Macrophages.

Authors:  Eija Nissilä; Pipsa Hakala; Katarzyna Leskinen; Angela Roig; Shahan Syed; Kok P M Van Kessel; Jari Metso; Carla J C De Haas; Päivi Saavalainen; Seppo Meri; Angeliki Chroni; Jos A G Van Strijp; Katariina Öörni; Matti Jauhiainen; T Sakari Jokiranta; Karita Haapasalo
Journal:  Front Immunol       Date:  2018-11-21       Impact factor: 7.561

Review 6.  Thrombotic Microangiopathy, an Unusual Form of Monoclonal Gammopathy of Renal Significance: Report of 3 Cases and Literature Review.

Authors:  Edward J Filippone; Eric D Newman; Li Li; Rakesh Gulati; John L Farber
Journal:  Front Immunol       Date:  2021-11-10       Impact factor: 7.561

Review 7.  A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application.

Authors:  Michael E O'Brien; Grace Murray; Debananda Gogoi; Azeez Yusuf; Cormac McCarthy; Mark R Wormald; Michelle Casey; Claudie Gabillard-Lefort; Noel G McElvaney; Emer P Reeves
Journal:  Int J Mol Sci       Date:  2022-02-23       Impact factor: 5.923

8.  Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial.

Authors:  Andrew S Bomback; David Kavanagh; Marina Vivarelli; Matthias Meier; Yaqin Wang; Nicholas J A Webb; Angelo J Trapani; Richard J H Smith
Journal:  Kidney Int Rep       Date:  2022-08-02

9.  Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles.

Authors:  Vivian P Vu; Geoffrey B Gifford; Fangfang Chen; Halli Benasutti; Guankui Wang; Ernest V Groman; Robert Scheinman; Laura Saba; Seyed Moein Moghimi; Dmitri Simberg
Journal:  Nat Nanotechnol       Date:  2019-01-14       Impact factor: 39.213

10.  Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency.

Authors:  Michael E O'Brien; Laura Fee; Niall Browne; Tomás P Carroll; Paula Meleady; Michael Henry; Karen McQuillan; Mark P Murphy; Mark Logan; Cormac McCarthy; Oliver J McElvaney; Emer P Reeves; Noel G McElvaney
Journal:  Thorax       Date:  2020-01-20       Impact factor: 9.139

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.